Blood Coagulation Testing Market Analysis

Blood Coagulation Testing Market Overview

Blood Coagulation Testing Market size was valued at USD 4.51 billion in 2023. The Blood Coagulation Testing Market industry is projected to grow from USD 4.81 billion in 2024 to USD 7.84 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.31% during the forecast period (2024 - 2032).

The increasing incidences of blood-acquired bleeding disorders and rising product launches by market players in the blood coagulation testing market are the major factors driving growth. However, the voluntary product recall by market players and the high cost associated with coagulation analyzers are expected to hamper the growth of the global market. Nevertheless, favorable government initiatives associated with bleeding disorders and a growing geriatric population across the globe are anticipated to create lucrative opportunities for the market.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Blood Coagulation Testing Trends

• 
  

  Increasing incidences of blood acquired bleeding disorders fuels market growth

  
  

The growing incidence of both acquired and inherited bleeding disorders, including hemophilia, von Willebrand Disease, and other similar conditions, is significantly driving the expansion of the blood coagulation testing market. As the prevalence of these disorders increases, both due to heightened awareness and better diagnostic capabilities, there is a rising demand for advanced coagulation tests. Inherited conditions like hemophilia and von Willebrand Disease are now more frequently identified and managed, while acquired bleeding disorders also contribute to a greater need for precise testing. For instance, as per the Centers for Disease Control and Prevention reported that Von Willebrand disease (VWD) affects approximately 1% of the general population, with no significant difference in frequency between men and women. However, women are more prone to experiencing symptoms of VWD due to increased bleeding during menstrual periods, pregnancy, and childbirth. From 2012 to 2023, over 33,456 individuals, including men, women, and children, sought treatment for VWD at hemophilia treatment centers. Moreover, in 2024, according to Pfizer, Inc. (US) stated that globally, over 200,000 individuals are known to have some form of hemophilia, but recent data suggest that the true number may be significantly higher, potentially exceeding 1.1 million. In the United States, while the precise prevalence of hemophilia is not fully determined, estimates indicate that approximately 33,000 individuals assigned male at birth are living with the condition across the country. Moreover, as per the World Federation for Hemophilia, there were 209,614 people with hemophilia, 165,379 with Hemophilia A, 33,076 with Hemophilia B, 11,159 with Hemophilia type unknown, 84,197 with von Willebrand disease and 53,215 Other bleeding disorders in 2020, worldwide.

Blood Coagulation Testing Segment Insights

Blood Coagulation Testing Product Insights

The Blood Coagulation Testing Market segmentation, based on product, includes consumables and instruments. The consumables segment held the largest market in 2023, and the instruments segment is the fastest growing segment during the forecast period. Rise in surgical procedures globally, particularly those involving cardiovascular systems, requires pre-operative and post-operative coagulation testing and introduction of new and improved blood coagulation testing consumables, along with regulatory approvals, is driving market growth by offering more accurate and reliable testing options.     

Blood Coagulation Testing Application Insights

The Blood Coagulation Testing Market segmentation, based on application, includes acquired bleeding disorders and inherited bleeding disorders. The acquired bleeding disorder segment held the largest market share in 2023 and is the fastest-growing segment during the forecast period. Increased awareness of the risks associated with acquired bleeding disorders, particularly among patients on long-term anticoagulant therapy, has led to more frequent monitoring and testing.

Figure 2: Blood Coagulation Testing Market, by Application, 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Blood Coagulation Testing Test Type Insights

The Blood Coagulation Testing Market segmentation, based on test type, includes prothrombin time testing, activated partial thromboplastin time (aPTT) testing, fibrinogen testing, activated clotting time testing, platelet function tests, and others. The prothrombin time testing segment held the largest market in 2023, and the activated partial thromboplastin time (aPTT) testing segment is the fastest growing segment during the forecast period. The growing number of people suffering from Vitamin K deficiency, liver disease, and bleeding disorders (such as hemophilia) is driving up demand for PT testing. Furthermore, PT is important in controlling warfarin therapy since it helps assess the anticoagulant's effectiveness and prevent problems such as excessive bleeding or clot formation.

The Blood Coagulation Testing Market segmentation, based on end user, includes hospitals and clinics, diagnostic centers, ambulatory care centers, and others. The hospitals and clinics segment held the largest market in 2023, and the diagnostic centers segment is the fastest growing segment during the forecast period. Growth of healthcare infrastructure, including the establishment of new hospitals and clinics, particularly in emerging markets, expands the reach and availability of coagulation testing services.

Blood Coagulation Testing Regional Insights

By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. The North America Blood Coagulation Testing market is experiencing significant growth, driven by factors such as the high incidence of coagulation disorders and advancements in technology and innovation. Furthermore, the region's well-established healthcare infrastructure, technological innovations, and favorable regulatory environment contribute to the market's expansion.

Further, the major countries will be study are US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: BLOOD COAGULATION TESTING MARKET BY REGION 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Blood Coagulation Testing market accounted for the second-largest market share due to robust healthcare infrastructure and supportive government health initiatives and funding. Furthermore, the Germany Blood Coagulation Testing provider attributed to hold the largest market share, and the France Blood Coagulation Testing providers is projected be the fastest growing market in the Europe region.

The Asia-Pacific Blood Coagulation Testing market is expected to be the fastest growing from 2023 to 2032 due to growing awareness of health management and early diagnosis among the population and favorable reimbursement policies for coagulation tests. Moreover, China Blood Coagulation Testing accounted to hold the largest market share, and the India Blood Coagulation Testing is projected to be the fastest growing market in the Asia-Pacific region.

Blood Coagulation Testing Key Market Players & Competitive Insights

The Blood Coagulation Testing Market is distinguished by the presence of numerous regional and local players catering to the Blood Coagulation Testing Market. Furthermore, the increasing incidences of blood-acquired bleeding disorders and rising product launches by market players in the blood coagulation testing are the major factors driving the growth of the Blood Coagulation Testing Market. Moreover, the rising Point-of-care (POC) testing solutions is also contributing as a significant growth driver for the market.

1. Hoffmann-La Roche Ltd (Roche) is one of the leading companies in the field of diagnostics and pharmaceuticals. It develops and markets products for diagnosis and treatment of anemia, cancer, anticoagulation therapy, cardiovascular diseases, diabetes, central nervous system, chlamydia, dermatology, gonorrhea, gout, hepatitis B and C, hemostasis disorders, HIV/AIDS, HPV, infectious diseases, and autoimmune diseases. The company specializes in the field of molecular diagnostics and medicines for oncology, virology, inflammation, metabolism, central nervous system, clinical chemistry, immunology, urinalysis, blood screening, genetics, infectious diseases, and microbiology. The firm operates in two major business segments, Pharmaceuticals and Diagnostics. The Pharmaceuticals segment offers a wide range of drugs for therapeutic areas, such as oncology, inflammation, neuroscience, infectious diseases, and ophthalmology. The segment is focused on transforming scientific excellence into effective patient treatments. By integrating pioneering research conducted at Roche, Genentech in the US, Chugai in Japan, and collaborating with over 250 partners globally, Roche leverages its extensive capabilities in clinical development, manufacturing, and commercial operations on a global scale. The diagnostics segment offers a wide range of tests for cancer and companion diagnostic tests. In over 100 countries, they provide the industry’s most extensive in vitro diagnostics testing portfolio, enhanced by clinical decision support, consultancy services, digital diagnostics, disease management, laboratory automation, and software solutions. These offerings deliver integrated solutions for laboratories, clinicians, and healthcare systems. Additionally, their autonomous research and development centers, along with alliances with over 250 external partners, promote a diverse range of scientific approaches and ensure agility in innovation. The company has a strong presence in North America, Europe, Asia, and the Middle East. The company distributes its products globally.

Moreover, In February 2024, Roche introduced three new coagulation tests for the oral Factor Xa inhibitors apixaban, edoxaban, and rivaroxaban in CE-mark-accepting countries. These tests are designed to aid clinical decision-making for patients using direct oral anticoagulants in managing conditions such as non-valvular atrial fibrillation, coronary artery disease, peripheral arterial disease, and venous thromboembolism.

Key Companies in the Blood Coagulation Testing market include.

• Hoffmann-La Roche Ltd.


• Abbott


• Siemens Healthcare


• Thermo Fisher Scientific Inc.


• Sysmex Corporation


• Werfen


• HemoSonics, LLC


• Micropoint Biotechnologies Co., Ltd.


• Helena Laboratories


• Meril Life Sciences Pvt. Ltd.

Blood Coagulation Testing Industry Developments

• In July 2024, Roche completed the acquisition of LumiraDx’s Point of Care technology. This transformative solution will enhance Roche’s diagnostics portfolio, integrating with their existing capabilities in Clinical Chemistry, Immunochemistry, Coagulation, and Molecular diagnostics across various disease areas.


• In April 2024, Sysmex Europe SE announced the opening of a new branch office, Sysmex Nordic ApS, in Finland. Sysmex aims to improve its market presence by increasing its sales and support network in the region.


• In February 2024, HemoSonics, LLC, announced that its Quantra Hemostasis System with QPlus and QStat Cartridges has been selected as a finalist in the 2024 Edison™ Awards. The company received this recognition in the health, medical, and biotechnology category for its Quantra Hemostasis System.

Blood Coagulation Testing Segmentation

Blood Coagulation Testing Product Outlook

• Consumables
  
  
  
  • Reagents
  
  
  • Test Kits
  
  
  
  


• Instruments

Blood Coagulation Testing Application Outlook

• Acquired Bleeding Disorders
  
  
  
  • Hemophilia
  
  
  • Von Willebrand Disease
  
  
  • Others
  
  
  
  


• Inherited Bleeding Disorders

Blood Coagulation Testing Test Type Outlook

• Prothrombin Time Testing


• Activated Partial Thromboplastin Time (aPTT) Testing


• Fibrinogen Testing


• Activated Clotting Time Testing


• Platelet Function Tests


• Others

Blood Coagulation Testing End User Outlook

• Hospitals and Clinics


• Diagnostic Centers


• Ambulatory Care Centers


• Others

Blood Coagulation Testing Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America